Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.34 |
| ▸ | FEN1 | P39748 | 4/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | CHUK | O15111 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | CCNC | P24863 | 1/20 | 0.30 |
| ▸ | CDK8 | P49336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20204677 | 0.83 | PDE2A (0.37) | FFAR4ALOX5APFEN1PDE4DCHUK | |
| SCHEMBL21325057 | 0.82 | RIPK1 (0.37) | ALOX5APFEN1RIPK1 | |
| SCHEMBL21690530 | 0.81 | FFAR4 (0.38) | FFAR4ALOX5APFEN1PDE4DCHUK | |
| SCHEMBL21325060 | 0.80 | ALOX5AP (0.33) | ALOX5APFEN1RIPK1 | |
| SCHEMBL21325056 | 0.79 | ALOX5AP (0.34) | FFAR4ALOX5APFEN1RIPK1EP300 | |
| SCHEMBL21325050 | 0.77 | HTR2B (0.35) | FFAR4ALOX5APFEN1RIPK1CNR2 | |
| SCHEMBL21325503 | 0.75 | FFAR4 (0.33) | FFAR4ALOX5APFEN1RIPK1CHUK | |
| SCHEMBL20202029 | 0.74 | RIPK1 (0.33) | ALOX5APFEN1RIPK1CHUK | |
| SCHEMBL21534010 | 0.74 | ALOX5AP (0.33) | FFAR4ALOX5APFEN1CHUK | |
| SCHEMBL21325055 | 0.72 | RIPK1 (0.33) | ALOX5APFEN1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174271-B2 | 6-membered uracil isosteres | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-11-16 | — | — | US | disclosed |
| US-11014924-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-05-25 | — | — | US | disclosed |
| US-10858344-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| US-20190330210-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| US-20190270756-A1 | 6-MEMBERED URACIL ISOSTERES | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174271-B2 | 6-membered uracil isosteres | UNG, DUT, DPYD | FFAR4 4698/4885ALOX5AP 3330/4885FEN1 52/4885 |
| US-20190330210-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | FFAR4 4718/4885ALOX5AP 2919/4885FEN1 108/4885 |
| US-10858344-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | FFAR4 4718/4885ALOX5AP 2919/4885FEN1 108/4885 |
| US-11014924-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | FFAR4 4718/4885ALOX5AP 2919/4885FEN1 108/4885 |
| US-20190270756-A1 | 6-MEMBERED URACIL ISOSTERES | UNG, DUT, DPYD | FFAR4 4698/4885ALOX5AP 3330/4885FEN1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.